CIM
HAE icon

Contravisory Investment Management’s Haemonetics HAE Stock Holding History

Contravisory Investment Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,507
Closed -$300K – 364
2023
Q4 		$300K Buy
3,507
+242
+7% +$20.9K 0.07% 172
2023
Q3 		$292K Buy
3,265
+37
+1% +$3.3K 0.08% 167
2023
Q2 		$275K Hold
3,228
– – 0.07% 175
2023
Q1 		$267K Buy
3,228
+3,147
+3,885% +$255K 0.08% 173
2022
Q4 		$6.37K Hold
81
– – ﹤0.01% 271
2022
Q3 		$6K Hold
81
– – ﹤0.01% 266
2022
Q2 		$5K Buy
+81
New +$4.79K ﹤0.01% 283
2015
Q4 		– Sell
-5,500
Closed -$178K – 223
2015
Q3 		$178K Hold
5,500
– – 0.04% 76
2015
Q2 		$227K Hold
5,500
– – 0.05% 66
2015
Q1 		$247K Buy
+5,500
New +$230K 0.05% 57

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Contravisory Investment Management's HAE Position: Q1 2024 in Review

Contravisory Investment Management sold out of Haemonetics (HAE) in Q1 2024, closing a stake of 3,507 shares — an estimated $300K sold.

Contravisory Investment Management first reported a position in HAE in Q1 2015 and held it in 10 quarters. The position peaked at $300K in Q4 2023. 298 funds tracked by Wall St. Rank hold HAE as of Q1 2024.

  • Contravisory Investment Management reported no remaining Haemonetics position as of Q1 2024 after selling out during the quarter.
  • Contravisory Investment Management sold 3,507 Haemonetics shares in Q1 2024, an estimated $300K.
  • Contravisory Investment Management first reported a position in Haemonetics in Q1 2015 and held it in 10 quarters.
  • Contravisory Investment Management's Haemonetics position peaked at $300K in Q4 2023.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q1 2024.

Based on Contravisory Investment Management's 13F filing for Q1 2024, filed 11 Apr 2024.